Bitte wählen Sie:

Universitätsklinikum Essen
Direkteinstieg:
Forschung

Publikationen

Hier finden Sie einen Auszug unserer Publikationen:

  • Calais J, Fendler WP et al. Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. J Nucl Med. 2018 Mar;59(3):434-441. (JIF2017: 7.4).

  • Lückerath K, Stuparu AD, Wei L, Kim W, Radu CG, Mona CE, Calais J, Rettig M, Reiter RE, Czernin J, Slavik J, Herrmann K, Eiber M, Wolfgang P. Fendler. Detection threshold and reproducibility of 68Ga-PSMA11 PET/CT in a mouse model of prostate cancer. Accepted J Nucl Med. 2018 March. (JIF2017: 7.4).

  • Lückerath K, Wei L, Fendler WP et al. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging Research. Accepted J Nucl Med. 2018 October. (JIF2017: 2.6).

  • Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, Baum RP, Kulkarni HR, Schmidt M, Drzezga A, Bartenstein P, Pfestroff A, Luster M, Lützen U, Marx M, Prasad V, Brenner W, Heinzel A, Mottaghy FM, Ruf J, Meyer PT, Heuschkel M, Eveslage M, Bögemann M, Fendler WP*, Krause BJ*. *authors contributed equally. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. J Nucl Med. 2017 Jan;58(1):85-90. doi: 10.2967/jnumed.116.183194. (JIF: 7.4).

  • Fendler WP et al. 68Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study. J Nucl Med. 2017 Apr 13. (JIF: 7.4).

  • Fendler WP et al. 177Lu-PSMA-617 radioligand therapy in a syngeneic model of murine prostate cancer. J Nucl Med. 2017 May 25. (JIF: 7.4).

  • Fendler WP et al. 68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients. J Nucl Med. 2017 Feb;58(2):307-311. doi: 10.2967/jnumed.116.179192. (JIF: 7.4).

  • Ruhlmann M, Binse I, Bockisch A, Rosenbaum-Krumme SJ. Initial [18F]FDG PET/CT in high-risk DTC patients. A three-year follow-up. Nuklearmedizin. 2016 Feb 2;55(3).[Epub ahead of print]
  • Ruhlmann V, Poeppel TD, Brandt AS, Grüneisen J, Ruhlmann M, Theysohn JM, Forsting M, Bockisch A, Umutlu L. 18F-FDG PET/MRI evaluation of retroperitoneal fibrosis: a simultaneous multiparametric approach for diagnosing active disease. Eur J Nucl Med Mol Imaging. 2016 Mar 11. [Epub ahead of print]
  • Lütje S, Sauerwein W, Lauenstein T, Bockisch A, Poeppel TD. In Vivo Visualization of Prostate-Specific Membrane Antigen in Adenoid Cystic Carcinoma of the Salivary Gland. Clin Nucl Med. 2016 Apr 6.
  • Ruhlmann M, Jentzen W, Ruhlmann V, Pettinato C, Rossi G, Binse I, Bockisch A, Rosenbaum-Krumme SJ. High Level of Agreement between Pretherapeutic 124I PET and Intratherapeutic 131I Images in Detecting Iodine-positive Thyroid Cancer Metastases. 2016 May; doi: 10.2967/jnumed.115.169649 [Epub ahead of print] Eur J Nucl Med Mol Imaging. 2016 Mar 11.[Epub ahead of print]
  • Sabet A, Binse I, Grafe H, Ezziddin S, Görges R, Poeppel TD, Bockisch A, Rosenbaum-Krumme SJ.Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative 124I-NaI-PET/CT in patients with papillary thyroid cancer. Eur J Nucl Med Mol Imaging. 2016 Apr 27. [Epub ahead of print]
  • Binse I, Poeppel TD, Ruhlmann M, Ezziddin S, Görges R, Sabet A, Beiderwellen K, Bockisch A, Rosenbaum-Krumme SJ. 68Ga-DOTATOC-PET/CT in patients with iodine- and 18F-FDG-negative differentiated thyroid carcinoma and elevated serum thyroglobulin. J Nucl Med. 2016 Mar 31. pii: jnumed.115.171942. [Epub ahead of print]
  • Binse I, Rosenbaum-Krumme SJ, Bockisch A. Imaging of differentiated thyroid carcinoma: 124I-PET/MRI may not be superior to 124I-PET/CT. Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1185-6. doi: 10.1007/s00259-016-3321-9.
  • Binse I, Poeppel TD, Ruhlmann M, Gomez B, Umutlu L, Bockisch A, Rosenbaum-Krumme SJ. Imaging with (124)I in differentiated thyroid carcinoma: is PET/MRI superior to PET/CT? Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1011-7. doi: 10.1007/s00259-015-3288-y. Epub 2015 Dec 19.
  • Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C, Gildehaus FJ, Stief CG, Gratzke C, Fendler WP.68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. Eur Urol. 2016 Oct;70(4):553-557. (JIF: 16.3).

  • Fendler WP et al. 68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer. J Nucl Med. 2016 Nov;57(11):1720-1725. (JIF: 6.6).

  • Delker A, Fendler WP et al. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):42-51. doi: 10.1007/s00259-015-3174-7. Epub 2015 Aug 29. (JIF: 7.3).

  • Lütje S, Heskamp S, Cornelissen AS, Poeppel TD, Broek SAMWvd, Rosenbaum-Krumme S, Bockisch A, Gotthardt M, Rijpkema M, Boerman OC. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. Theranostics 2015; 5(12):1388-1401.
  • Jentzen W, Bockisch A, Ruhlmann M: Assessment of Simplified Blood Dose Protocols for the Estimation of the Maximum Tolerable Activity in Thyroid Cancer Patients Undergoing Radioiodine Therapy Using 124I. J Nucl Med. 2015 Jun;56(6):832-8.
  • Schlamann M, Ruhlmann V, Quick HH: Hybridbildgebung in der Neuroradiologie. Der Neurologe & Psychiater 2015; 16 (4): 40-46.
  • Beiderwellen K, Grueneisen J, Ruhlmann V, Buderath P, Aktas B, Heusch P, Kraff O, Forsting M, Lauenstein TC, Umutlu L: [(18)F]FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results. Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):56-65.
  • Schaarschmidt B, Buchbender C, Gomez B, Rubbert C, Hild F, Köhler J, Grueneisen J, Reis H, Ruhlmann V, Wetter A, Quick HH, Antoch G, Heusch P: Thoracic staging of non-small-cell lung cancer using integrated 18F-FDG PET/MR imaging: diagnostic value of different MR sequences. Eur J Nucl Med Mol Imaging. 2015 Apr 8.
  • Schaarschmidt BM, Grueneisen J, Heusch P, Gomez B, Umutlu L, Ruhlmann V, Rosenbaum-Krumme S, Antoch G, Buchbender C: Does 18F-FDG PET/MRI reduce the number of indeterminate abdominal incidentalomas compared with 18F-FDG PET/CT? Nucl Med Commun. 2015 Mar 10.
  • Schaarschmidt BM, Buchbender C, Nensa F, Grueneien J, Gomez B, Köhler J, Reis H, Ruhlmann V, Umutlu L, Heusch P: Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in lymph node metastases of non-small cell lung cancer (NSCLC) patients using hybrid 18F-FDG PET/MRI. PLoS One. 2015 Jan 9;10(1):e0116277. doi: 10.1371/journal.pone.0116277. eCollection 2015.
  • Beiderwellen K, Grueneisen J, Ruhlmann V, Buderath P, Aktas B, Heusch P, Kraff O, Forsting M, Lauenstein TC, Umutlu L: [(18)F]FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results. Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):56-65. doi: 10.1007/s00259-014-2902-8. Epub 2014 Sep 16.
  • Heusch P, Nensa F, Schaarschmidt B, Sivanesapillai R, Beiderwellen K, Gomez B, Köhler J, Reis H, Ruhlmann V, Buchbender C: Diagnostic accuracy of whole-body PET/MRI and whole-body PET/CT for TNM staging in oncology. Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):42-8.
  • Schelhorn J, Best J, Reinboldt MP, Dechêne A, Gerken G, Ruhlmann M, Lauenstein TC, Antoch G, Kinner S: Does diffusion-weighted imaging improve therapy response evaluation in patients with hepatocellular carcinoma after radioembolization? comparison of MRI using Gd-EOB-DTPA with and without DWI. J Magn Reson Imaging. 2015 Sep;42(3):818-27.
  • Schelhorn J, Richly H, Ruhlmann M, Lauenstein TC, Theysohn JM: A single-center experience in radioembolization as salvage therapy of hepatic metastases of uveal melanoma. Acta Radiol Open. 2015 Apr 6;4(4):2047981615570417.
  • Schelhorn J, Best J, Reinboldt MP, Gerken G, Ruhlmann M, Lauenstein TC, Antoch G, Kinner S: Therapy response assessment after radioembolization of patients with hepatocellular carcinoma--comparison of MR imaging with gadolinium ethoxybenzyl diethylenetriamine penta-acetic acid and gadobutrol. J Vasc Interv Radiol. 2015 Jul;26(7):972-9.
  • Schaarschmidt BM, Heusch P, Buchbender C, Ruhlmann M, Bergmann C, Ruhlmann V, Schlamann M, Antoch G, Forsting M, Wetter A: Locoregional tumour evaluation of squamous cell carcinoma in the head and neck area: a comparison between MRI, PET/CT and integrated PET/MRI. Eur J Nucl Med Mol Imaging. 2015 Aug 6.
  • Theysohn JM, Ruhlmann M, Müller S, Dechene A, Best J, Haubold J, Umutlu L, Gerken G, Bockisch A, Lauenstein TC: Radioembolization with Y-90 Glass Microspheres: Do We Really Need SPECT-CT to Identify Extrahepatic Shunts? PLoS One. 2015 Sep 3;10(9):e0137587.
  • Barsegian V, Hueben C, Mueller SP, Poeppel TD, Horn PA, Bockisch A, Lindemann M: Impairment of lymphocyte function following yttrium-90 DOTATOC therapy. Cancer Immunol Immunother. 2015
  • Farahati J, Nagarajah J, Gilman E, Mahjoob S, Zohreh M, Rosenbaum-Krumme S, Bockisch A, Zakavi SR: Ethnicity, Clothing Style, and Body Mass Index are Significant Predictors of Vitamin D Insufficiency in Germany. Endocr Pract. 2015;21(2): 122-7
  • Nensa F, Tezgah E, Poeppel T, Nassenstein K, Schlosser T: Diagnosis and treatment response evaluation of cardiac sarcoidosis using positron emission tomography/magnetic resonance imaging. Eur Heart J. 2015;36(9): 550
  • Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A, Krause BJ: FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2): 328-54
  • Gorla R, Erbel R, Kuehl H, Kahlert P, Tsagakis K, Jakob H, Mahabadi AA, Schlosser T, Bockisch A, Eggebrecht H, Bossone E, Jánosi RA: Prognostic value of (18)F-fluorodeoxyglucose PET-CT imaging in acute aortic syndromes: comparison with serological biomarkers of inflammation. Int J Cardiovasc Imaging. 2015;
  • Tiedje V, Schmid KW, Weber F, Bockisch A, Führer D: Differentiated thyroid cancer. Internist (Berl). 2015;56(2): 153-68
  • Clift AK, Faiz O, Al-Nahhas A, Bockisch A, Liedke MO, Schloericke E, Wasan H, Martin J, Ziprin P, Moorthy K, Frilling A: Role of Staging in Patients with Small Intestinal Neuroendocrine Tumours. J Gastrointest Surg. 2015;
  • Jentzen W, Bockisch A, Ruhlmann M: Assessment of Simplified Blood Dose Protocols for the Estimation of the Maximum Tolerable Activity in Thyroid Cancer Patients Undergoing Radioiodine Therapy Using 124I. J Nucl Med. 2015;56(6): 832-8
  • Nensa F, Tezgah E, Poeppel TD, Jensen CJ, Schelhorn J, Köhler J, Heusch P, Bruder O, Schlosser T, Nassenstein K: Integrated 18F-FDG PET/MR Imaging in the Assessment of Cardiac Masses: A Pilot Study. J Nucl Med. 2015;56(2): 255-60
  • Jentzen W: An Improved Iterative Thresholding Method to Delineate PET Volumes Using the Delineation-Averaged Signal Instead of the Enclosed Maximum Signal. J Nucl Med Technol. 2015;43(1): 28-35
  • Barakat E, Lauenstein T, Bockisch A, Gerken G, Schlaak JF: In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? Liver Int. 2015;35(2): 627-35
  • Jentzen W, Moldovan AS, Ruhlmann M, Görges R, Bockisch A, Rosenbaum-Krumme S: Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimation. Nuklearmedizin. 2015;54(3): 137-43
  • Poeppel TD, Boy C, Bockisch A, Kotzerke J, Buchmann I, Ezziddin S, Scheidhauer K, Krause BJ, Schmidt D, Amthauer H, Rösch F, Nagarajah J, Führer D, Lahner H, Pöpperl G, Hörsch D, Walter MA, Baum RP: Peptide receptor radionuclide therapy for patients with somatostatin receptor expressing tumours. German Guideline (S1). Nuklearmedizin. 2015;54(1): 1-11
  • Theysohn JM, Ruhlmann M, Müller S, Dechene A, Best J, Haubold J, Umutlu L, Gerken G, Bockisch A, Lauenstein TC: Radioembolization with Y-90 Glass Microspheres: Do We Really Need SPECT-CT to Identify Extrahepatic Shunts? PLoS ONE. 2015;10(9): e0137587
  • Jentzen W, Richter M, Poeppel TD, Schmitz J, Brandau W, Bockisch A, Binse I: Discrepant salivary gland response after radio iodine and MIBG therapies. Q J Nucl Med Mol Imaging. 2015;
  • Nensa F, Poeppel T, Tezgah E, Heusch P, Nassenstein K, Mahabadi AA, Forsting M, Bockisch A, Erbel R, Heusch G, Schlosser T: Integrated FDG PET/MR Imaging for the Assessment of Myocardial Salvage in Reperfused Acute Myocardial Infarction. Radiology. 2015;276(2): 400-7
  • Ruhlmann V, Heusch P, Kühl H, Beiderwellen K, Antoch G, Forsting M, Bockisch A, Buchbender C, Quick HH. Potential influence of Gadolinium contrast on image segmentation in MR-based attenuation correction with Dixon sequences in whole-body 18F-FDG PET/MR. MAGMA. 2015 Dec 14. [Epub ahead of print]
  • Ruhlmann V, Ruhlmann M, Beiderwellen K, Lauenstein T: Ganzkörper-MRT. Der Nuklearmediziner 2014; 37: 83-89.
  • Ruhlmann M, Stebner V, Görges R, Farahati J, Simon D, Bockisch A, Rosenbaum-Krumme S, Nagarajah J: Diagnosis of hyperfunctional thyroid nodules: impact of US-elastography. Nuklearmedizin. 2014;53(5):173-7.
  • Beiderwellen K, Ruhlmann V, Lazik A: MRT des Skelettsystems in der Onkologie. Der Nuklearmediziner 2014; 37: 73-76.
  • Stegger L, Ruhlmann V: PET/MRT - Ein neues Verfahren der klinischen Hybridbildgebung. Der Nuklearmediziner 2014; 37: 101-108.
  • Grueneisen J, Beiderwellen K, Heusch P, Gratz M, Schulze-Hagen A, Heubner M, Kinner S, Forsting M, Lauenstein T, Ruhlmann V, Umutlu L: Simultaneous Positron Emission Tomography/Magnetic Resonance Imaging for Whole-Body Staging in Patients With Recurrent Gynecological Malignancies of the Pelvis: A Comparison to Whole-Body Magnetic Resonance Imaging Alone. Invest Radiol. 2014 Jul 9.
  • Beiderwellen K, Huebner M, Heusch P, Grueneisen J, Ruhlmann V, Nensa F, Kuehl H, Umutlu L, Rosenbaum-Krumme S, Lauenstein TC: Whole-body [¹?F]FDG PET/MRI vs. PET/CT in the assessment of bone lesions in oncological patients: initial results. Eur Radiol. 2014 Aug;24(8):2023-30.
  • Grueneisen J, Beiderwellen K, Heusch P, Buderath P, Aktas B, Gratz M, Forsting M, Lauenstein T, Ruhlmann V, Umutlu L: Correlation of standardized uptake value and apparent diffusion coefficient in integrated whole-body PET/MRI of primary and recurrent cervical cancer. PLoS One. 2014 May 7;9(5):e96751.
  • Jentzen W, Richter M, Nagarajah J, Poeppel TD, Brandau W, Dawes C, Bockisch A, Binse I. Chewing-gum stimulation did not reduce the absorbed dose to salivary glands during radioiodine treatment of thyroid cancer as inferred from pre-therapy (124)I PET/CT imaging. EJNMMI Phys. 2014 Dec;1(1):100. doi: 10.1186/s40658-014-0100-1. Epub 2014 Dec 6.
  • Binse I, Ueberberg B, Sandalcioglu IE, Flitsch J, Luedecke DK, Mann K, Petersenn S. Expression analysis of GADD45y, MEG3, and p8 in pituitary adenomas. Horm Metab Res. 2014 Aug;46(9):644-50. doi: 10.1055/s-0034-1383566. Epub 2014 Aug 15.
  • Hartung V, Ruhlmann M, Bockisch A, Nagarajah J: Tumor Imaging with 123/131I-MIBG-SPECT. SPECT Technology, Procedures And Applications 2013; 7: 133-146.
  • Hartung-Knemeyer V, Beiderwellen KJ, Buchbender C, Kuehl H, Lauenstein TC, Bockisch A, Poeppel TD: Optimizing Positron Emission Tomography Image Acquisition Protocols in Integrated Positron Emission Tomography/Magnetic Resonance Imaging. Invest Radiol. 2013 Feb 8
  • Buchbender C, Hartung-Knemeyer V, Beiderwellen K, Heusch P, Kühl H, Lauenstein TC, Forsting M, Antoch G, Heusner TA: Diffusion-weighted imaging as part of hybrid PET/MRI protocols for whole-body cancer staging: Does it benefit lesion detection? Eur J Radiol. 2013 Feb 18.
  • Heusch P, Buchbender C, Beiderwellen K, Nensa F, Hartung-Knemeyer V, Lauenstein TC, Bockisch A, Forsting M, Antoch G, Heusner TA: Standardized uptake values for [(18)F] FDG in normal organ tissues: Comparison of whole-body PET/CT and PET/MRI. Eur J Radiol. 2013 Feb 7.
  • Buchbender C, Hartung-Knemeyer V, Heusch P, Heusner TA, Beiderwellen K, Wittsack HJ, Kühl H, Forsting M, Bockisch A, Antoch G, Lanzman RS: Does positron emission tomography data acquisition impact simultaneous diffusion-weighted imaging in a whole-body PET/MRI system? Eur J Radiol. 2013 Feb;82(2):380-4.
  • Buchbender C, Hartung-Knemeyer V, Forsting M, Antoch G, Heusner TA: Positron emission tomography (PET) attenuation correction artefacts in PET/CT and PET/MRI. Br J Radiol. 2013 May;86(1025):20120570.
  • Beiderwellen KJ, Poeppel TD, Hartung-Knemeyer V, Buchbender C, Kuehl H, Bockisch A, Lauenstein TC: Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results. Invest Radiol. 2013 May;48(5):273-9.
  • Heusch P, Köhler J, Wittsack HJ, Heusner TA, Buchbender C, Poeppel TD, Nensa F, Wetter A, Gauler T, Hartung V, Lanzman RS: Hybrid [18F]-FDG PET/MRI including non-Gaussian diffusion-weighted imaging (DWI): Preliminary results in non-small cell lung cancer (NSCLC). Eur J Radiol. 2013 Jul 4.
  • Beiderwellen K, Gomez B, Buchbender C, Hartung V, Poeppel TD, Nensa F, Kuehl H, Bockisch A, Lauenstein TC: Depiction and characterization of liver lesions in whole body [¹?F]-FDG PET/MRI. Eur J Radiol. 2013 Nov;82(11):e669-75.

9. Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors. Recent Results Cancer Res. 2013;194:353-71. doi: 10.1007/978-3-642-27994-2_18.

  • Hartung-Knemeyer V, Müller S, Nagarajah J, Lahner H, Broecker-Preuss M, Bockisch A, Görges R: Influence of the calcitonin assay on the definition of biochemical cure in patients with medullary thyroid carcinoma. Nuklearmedizin. 2012 Aug 6;51(4):125-32. German.
  • Hartung-Knemeyer V, Nagarajah J, Jentzen W, Ruhlmann M, Freudenberg LS, Stahl AR, Bockisch A, Rosenbaum-Krumme SJ: Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of preceding radioiodine therapies. Ann Nucl Med. 2012 Jul 17.
  • Hartung-Knemeyer V, Rosenbaum-Krumme S, Buchbender C, Pöppel T, Brandau W, Jentzen W, Antoch G, Forsting M, Bockisch A, Kühl H: Malignant pheochromocytoma imaging with [124I]mIBG PET/MR. J Clin Endocrinol Metab. 2012 Nov;97(11):3833-4. doi: 10.1210/jc.2012-1958. Epub 2012 Sep 7.
  • Nagarajah J, Dannat T, Hartung V, Bockisch A, Rosenbaum-Krumme S: 18F-fluoride PET/CT for bone scanning. Role of attenuation correction. Nuklearmedizin. 2012;51(3):84-7.
  • Hahn S, Hecktor J, Grabellus F, Hartung V, Pöppel T, Kimmig R, Forsting M, Antoch G, Heusner TA: Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients. Acta Radiol. 2012 Jun 1;53(5):518-23.
  • Riegger C, Köninger A, Forsting M, Hartung V, Otterbach F, Kimmig R, Bockisch A, Antoch G: Comparison of the diagnostic accuracy of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients. Acta Radiol. 2012 Dec 1;53(10):1092-8.
  • Rosenbaum-Krumme SJ, Görges R, Bockisch A, Binse I. 18F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. Eur J Nucl Med Mol Imaging. 2012 Sep;39(9):1373-80. doi: 10.1007/s00259-012-2065-4. Epub 2012 Jun 21.
  • Bockisch A: Matched pairs for radionuclide-based imaging and therapy. Eur J Nucl Med Mol Imaging 2011.
  • Boy C, Heusner TA, Poeppel TD, Redmann-Bischofs A, Unger N, Jentzen W, Brandau W, Mann K, Antoch G, Bockisch A, Petersenn S: (68)Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUV(max). Eur J Nucl Med Mol Imaging 2011.
  • Freudenberg LS, Jentzen W, Stahl A, Bockisch A, Rosenbaum-Krumme SJ: Clinical applications of (124)I-PET/CT in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2011.
  • Heusner TA, Hahn S, Jonkmanns C, Kuemmel S, Otterbach F, Hamami ME, Stahl AR, Bockisch A, Forsting M, Antoch G: Diagnostic accuracy of fused positron emission tomography/magnetic resonance mammography: initial results. Br J Radiol 2011, 84:126-135
  • Jentzen W, Freudenberg L, Bockisch A: Quantitative imaging of 124I with PET/ CT in pretherapy lesion dosimetry Effects impairing image quantification and their corrections. Q J Nucl Med Mol Imaging 2011, 55:21-43.
  • Musholt TJ, Clerici T, Dralle H, Frilling A, Goretzki PE, Hermann MM, Kußmann J, Lorenz K, Nies C, Schabram J, et al: German Association of Endocrine Surgeons practice guidelines for the surgical treatment of benign thyroid disease. Langenbecks Arch Surg 2011.
  • Stahl AR, Heusner TA, Hartung V, Nagarajah J, Bockisch A, Hahn S, Antoch G, Jentzen W: Time course of tumor SUV in 18F-FDG PET of breast cancer: presentation of a simple model using a single reference point for time corrections of tumor SUVs. J Nucl Med 2011, 52:18-23.
  • Walter MA, Benz MR, Hildebrandt IJ, Laing RE, Hartung V, Damoiseaux RD, Bockisch A, Phelps ME, Czernin J, Weber WA: Metabolic imaging allows early prediction of response to vandetanib. J Nucl Med 2011, 52:231-240.
  • Stoffels I, Poeppel T, Boy C, Mueller S, Wichmann F, Dissemond J, Schadendorf D, Rosenbaum-Krumme S, Klode J.: Radio-guided surgery: advantages of a new portable Y-camera (Sentinella(®) ) for intraoperative real time imaging and detection of sentinel lymph nodes in cutaneous malignancies. J Eur Acad Dermatol Venereol
  • Stoffels I, Dissemond J, Poeppel T, Klötgen K, Hillen U, Körber A, Schadendorf D, Klode J.: Advantages of preoperative ultrasound in conjunction with lymphoscintigraphy in detecting malignant melanoma metastases in sentinel lymph nodes: a retrospective analysis in 221 patients with malignant melanoma AJCC Stages I and II. J Eur Acad Dermatol Venereol
  • Stoffels I, Dissemond J, Körber A, Hillen U, Poeppel T, Schadendorf D, Klode: Reliability and cost-effectiveness of sentinel lymph node excision under local anaesthesia versus general anaesthesia for malignant melanoma: a retrospective analysis in 300 patients with malignant melanoma AJCC Stages I and II. J Eur Acad Dermatol Venereol
  • Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 2011 Dec;52(12):1864-70. doi: 10.2967/jnumed.111.091165. Epub 2011 Nov 9
  • Antoch G, Mueller SP, Hamami M, Heusner TA, Ertle J, Hilgard P, Forsting M, Bockisch A: [Selective internal radiotherapy (SIRT) for hepatocellular carcinoma]. Rofo 2010, 182:660-670.
  • Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, Oyen WJ, Kotzerke J, Hoekstra OS, Pruim J, et al: FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010, 37:181-200.
  • Eising EG, Hughes J, Nolte F, Jentzen W, Bockisch A: Burn injury by nuclear magnetic resonance imaging. Clin Imaging 2010, 34:293-297.
  • Eising EG, Jentzen W: Calcification-related absorption in thyroid scintigraphy. Nuklearmedizin 2010, 49:13-18.
  • Freudenberg LS, Frömke C, Petrich T, Marlowe RJ, Koska WW, Brandau W, Eising EG, Knust EJ, Bockisch A, Jentzen W: Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer. Exp Clin Endocrinol Diabetes 2010, 118:393-399.
  • Freudenberg LS, Jentzen W, Petrich T, Frömke C, Marlowe RJ, Heusner T, Brandau W, Knapp WH, Bockisch A: Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons. Eur J Nucl Med Mol Imaging 2010, 37:2267-2276.
  • Freudenberg LS, Nattland A, Jonas G, Beyer T, Bockisch A: [E-learning in nuclear medicine - a nationwide survey in Germany]. Nuklearmedizin 2010, 49:161-166.
  • Freudenberg LS, Rosenbaum SJ, Beyer T, Bockisch A, Antoch G: PET versus PET/CT dual-modality imaging in evaluation of lung cancer. Thorac Surg Clin 2010, 20:25-30.
  • Frilling A, Sotiropoulos GC, Radtke A, Malago M, Bockisch A, Kuehl H, Li J, Broelsch CE: The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg 2010, 252:850-856.
  • Grabellus F, Sheu SY, Bachmann HS, Lehmann N, Otterbach F, Heusner TA, Antoch G, Bockisch A, Kimmig R, Schmid KW, Stahl AR: The XbaI G>T polymorphism of the glucose transporter 1 gene modulates 18F-FDG uptake and tumor aggressiveness in breast cancer. J Nucl Med 2010, 51:1191-1197.
  • Hahn S, Bauer S, Heusner TA, Ebeling P, Hamami ME, Stahl A, Forsting M, Bockisch A, Antoch G: Postoperative FDG-PET/CT staging in GIST: Is there a benefit following R0 resection? Eur J Radiol 2010.
  • Hahn S, Heusner T, Zhou X, Zhan Y, Peng Z, Hamami M, Forsting M, Bockisch A, Antoch G: Computer-Aided Detection (CAD) and Assessment of Malignant Lesions in the Liver and Lung using a Novel PET/CT Software Tool: Initial Results. Rofo 2010, 182:243-247.
  • Heusner TA, Hamami ME, Ertle J, Hahn S, Poeppel T, Hilgard P, Bockisch A, Forsting M, Antoch G: Angiography-based C-arm CT for the assessment of extrahepatic shunting before radioembolization. Rofo 2010, 182:603-608.
  • Heusner TA, Kuemmel S, Koeninger A, Hamami ME, Hahn S, Quinsten A, Bockisch A, Forsting M, Lauenstein T, Antoch G, Stahl A: Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging 2010, 37:1077-1086.
  • Hilgard P, Hamami M, Fouly AE, Scherag A, Müller S, Ertle J, Heusner T, Cicinnati VR, Paul A, Bockisch A, et al: Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010, 52:1741-1749.
  • Jentzen W: Experimental investigation of factors affecting the absolute recovery coefficients in iodine-124 PET lesion imaging. Phys Med Biol 2010, 55:2365-2398.
  • Jentzen W, Balschuweit D, Schmitz J, Freudenberg L, Eising E, Hilbel T, Bockisch A, Stahl A: The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging. Eur J Nucl Med Mol Imaging 2010, 37:2298-2306.
  • Jentzen W, Hobbs RF, Stahl A, Knust J, Sgouros G, Bockisch A: Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2010, 37:884-895.
  • Kotzerke J, Dietlein M, Grünwald F, Bockisch A: [PET and diagnostic technology evaluation in a global clinical process. DGN's point of view]. Nuklearmedizin 2010, 49:6-12.
  • Matuszczyk A, Petersenn S, Voigt W, Kegel T, Dralle H, Schmoll HJ, Bockisch A, Mann K: Chemotherapy with paclitaxel and gemcitabine in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res 2010, 42:61-64.
  • Stergar H, Krause BJ, Eschmann SM, Juergens KU, Kuehl H, Pfannenberg AC, Stollfuss J, Weckesser M, Bockisch A: Lesion concordance, image quality and artefacts in PET/CT: results of a multicenter study. Nuklearmedizin 2010, 49:129-137.
  • Klode J, Poeppel T, Boy C, Mueller S, Schadendorf D, Körber A, Stoffels I, Dissemond J.: Advantages of preoperative hybrid SPECT/CT in detection of sentinel lymph nodes in cutaneous head and neck malignancies. J Eur Acad Dermatol Venereol
  • Klode J, Dissemond J, Grabbe S, Hillen U, Poeppel T, Boeing C.: Sentinel lymph node excision and PET-CT in the initial stage of malignant melanoma: a retrospective analysis of 61 patients with malignant melanoma in American Joint Committee on Cancer stages I and II. Dermatol Surg
  • Klode J, Poeppel T, Boy C, Mueller S, Schadendorf D, Körber A, Stoffels I, Dissemond J.: Advantages of preoperative hybrid SPECT/CT in detection of sentinel lymph nodes in cutaneous head and neck malignancies. J Eur Acad Dermatol Venereol
  • Klode J, Dissemond J, Grabbe S, Hillen U, Poeppel T, Boeing C. Sentinel lymph node excision and PET-CT in the initial stage of malignant melanoma: a retrospective analysis of 61 patients with malignant melanoma in American Joint Committee on Cancer stages I and II. Dermatol Surg
  • Koppelstaetter F, Poeppel TD, Siedentopf CM, Ischebeck A, Kolbitsch C, Mottaghy FM, Felber SR, Jaschke WR, Krause BJ.Caffeine and cognition in functional magnetic resonance imaging. J Alzheimers Dis
  • Antoch G, Bockisch A: Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur J Nucl Med Mol Imaging 2009, 36 Suppl.:113-120.
  • Bockisch A: Nuclear Medicine. Nuklearmedizin 2009, 48:N61-N62.
  • Bockisch A, Freudenberg LS, Schmidt D, Kuwert T: Hybrid imaging by SPECT/CT and PET/CT: proven outcomes in cancer imaging. Semin Nucl Med 2009, 39:276-289.
  • Bockisch A, Grünwald F, Kotzerke J: [In Process Citation]. Nuklearmedizin 2009, 48:55-57.
  • Eckstein A, Mann K, Kahaly GJ, Grussendorf M, Reiners C, Feldkamp J, Quadbeck B, Bockisch A, Schott M: [Role of TSH receptor autoantibodies for the diagnosis of Graves' disease and for the prediction of the course of hyperthyroidism and ophthalmopathy. Recommendations of the Thyroid Section of the German Society of Endocrinology]. Med Klin (Munich) 2009, 104:343-348.
  • El Fouly A, Ertle J, Antoch G, Hamami M, Paul A, Bockisch A, Gerken G, Hilgard P: RESPONSE RATE ACCORDING TO WHO, RECIST AND EASL CRITERIA AFTER RADIOEMBOLIZATION OF YTTRIUM-90 GLASS MICROSPHERES IN ADVANCED HEPATOCELLULAR CARCINOMA: A EUROPEAN PILOT PHASE II STUDY. J Hepatol 2009, 50:51.
  • Freudenberg L, Müller S, Beyer T, Bockisch A: Subjective perception of radioactivity - No change post successful treatment with radioiodine. Nuklearmedizin 2009, 48:84-88.
  • Freudenberg LS, Holl G, Müller SP, Rosenbaum-Krumme SJ, Sciuk J, Bockisch A: [Impact of nuclear medicine imaging techniques for lymph node surgery.]. Urologe 2009, 48:19-25.
  • Freudenberg LS, Müller SP, Bockisch A: Subjective perceptions of patients undergoing radioiodine therapy: why should we know about them? Eur J Nucl Med Mol Imaging 2009, 36:1743-1744.
  • Frilling A, Li J, Malamutmann E, Schmid KW, Bockisch A, Broelsch CE: Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg 2009, 96:175-184.
  • Hamami ME, Poeppel TD, Müller S, Heusner T, Bockisch A, Hilgard P, Antoch G: SPECT/CT with 99mTc-MAA in Radioembolization with 90Y Microspheres in Patients with Hepatocellular Cancer. J Nucl Med 2009, 50:688-692.
  • Heusner T, Gölitz P, Hamami M, Eberhardt W, Esser S, Forsting M, Bockisch A, Antoch G: "One-stop-shop" staging: Should we prefer FDG-PET/CT or MRI for the detection of bone metastases? Eur J Radiol 2009.
  • Heusner TA, Hahn S, Hamami ME, Kim UH, Baumeister R, Forsting M, Stahl A, Bockisch A, Antoch G: Gastrointestinal 18F-FDG accumulation on PET without a corresponding CT abnormality is not an early indicator of cancer development. Eur Radiol 2009, 19:2171-2179.
  • Heusner TA, Hahn S, Hamami ME, Kögel S, Forsting M, Bockisch A, Antoch G, Stahl AR: Incidental head and neck (18)F-FDG uptake on PET/CT without corresponding morphological lesion: early predictor of cancer development? Eur J Nucl Med Mol Imaging 2009, 36:1397-1406.
  • Heusner TA, Kuemmel S, Hahn S, Koeninger A, Otterbach F, Hamami ME, Kimmig KR, Forsting M, Bockisch A, Antoch G, Stahl A: Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging 2009, 36:1543-1550.
  • Hilgard P, Antoch G, El Fouly AH, Hamami M, Scherag A, Ertle JM, Paul A, Bockisch A, Gerken G: RADIOEMBOLIZATION WITH Y-90 GLASS MICROSPHERES IN ADVANCED HEPATOCELLULAR CARCINOMA: SAFETY, RESPONSE AND SURVIVAL IN A EUROPEAN COHORT OF 108 PATIENTS. Hepatology 2009, 50 Suppl.:1680.
  • Hilgard P, Müller S, Hamami M, Sauerwein WS, Haberkorn U, Gerken G, Antoch G: [Selective internal radiotherapy (radioembolization) and radiation therapy for HCC--current status and perspectives]. Z Gastroenterol 2009, 47:37-54.
  • Kinner S, Veit-Haibach P, Lauenstein TC, Bockisch A, Antoch G: Water-equivalent oral contrast agents in dual-modality PET/computed tomography scanning: does a little barium make the difference? Nucl Med Commun 2009, 30:206-209.
  • Pan Y, Leifert A, Ruau D, Neuss S, Bornemann J, Schmid G, Brandau W, Simon U, Jahnen-Dechent W: Gold nanoparticles of diameter 1.4 nm trigger necrosis by oxidative stress and mitochondrial damage. Small 2009, 5:2067-2076.
  • Poeppel TD, Krause BJ, Heusner TA, Boy C, Bockisch A, Antoch G: PET/CT for the staging and follow-up of patients with malignancies. Eur J Radiol 2009, 70:382-392.
  • Stahl AR, Freudenberg L, Bockisch A, Jentzen W: A novel view on dosimetry-related radionuclide therapy: presentation of a calculatory model and its implementation for radioiodine therapy of metastasized differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2009, 36:1147-1155.
  • Stattaus J, Hahn S, Gauler T, Eberhardt W, Mueller SP, Forsting M, Ladd SC: Osteoblastic response as a healing reaction to chemotherapy mimicking progressive disease in patients with small cell lung cancer. Eur Radiol 2009, 19:193-200.
  • Veit-Haibach P, Vogt FM, Jablonka R, Kuehl H, Bockisch A, Beyer T, Dahmen G, Rosenbaum S, Antoch G: Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma. Eur J Nucl Med Mol Imaging 2009, 36:910-918.
  • Beyer T, Pietrzyk U, Knoess C, Vollmar S, Wienhard K, Kracht L, Bockisch A, Maderwald S, Kühl H, Fitzek M: Multi-modality imaging of uveal melanomas using combined PET/CT, high-resolution PET and MR imaging. Nuklearmedizin 2008, 47:73-79.
  • Beyer T, Weigert M, Quick HH, Pietrzyk U, Vogt F, Palm C, Antoch G, Müller SP, Bockisch A: MR-based attenuation correction for torso-PET/MR imaging: pitfalls in mapping MR to CT data. Eur J Nucl Med Mol Imaging 2008, 35:1142-1146.
  • Bockisch A, Laniado M: Only trained staff defines indication. Dtsch Arztebl Int 2008, 105:498-499; author reply 499.
  • Boy C, Meyer PT, Kircheis G, Holschbach MH, Herzog H, Elmenhorst D, Kaiser HJ, Coenen HH, Haussinger D, Zilles K, Bauer A: Cerebral A(1) adenosine receptors (A(1)AR) in liver cirrhosis. Eur J Nucl Med Mol Imaging 2008, 35:589-597.
  • Ertlel JM, Antoch G, Hamami M, Bockisch A, Gerken G, Hilgard P: Internal radiotherapy with 90Yttrium glass microspheres (therasphere) for locally advanced hepatocellular carcinoma: Prospective validation of safety and efficacy in a european pilot study. J Hepatol 2008, 48:370.
  • Farmakis G, Brandau W, Hellwig D, Wollenweber F, Schaefer A, Kirsch CM, Samnick S: PET imaging with p-[I-124]iodo-l-phenylalanine as a new tool for diagnosis and postoperative control in patients with glioma. Clin Nucl Med 2008, 33:441-442.
  • Freudenberg LS, Antoch G, Frilling A, Jentzen W, Rosenbaum SJ, Kühl H, Bockisch A, Görges R: Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET. Eur J Nucl Med Mol Imaging 2008, 35:950-957.
  • Freudenberg LS, Gauler T, Görges R, Bauer S, Stergar H, Antoch G, Bockisch A, Schütte J: Somatostatin receptor scintigraphy in advanced renal cell carcinoma. Results of a phase II-trial of somatostatine analogue therapy in patients with advanced RCC. Nuklearmedizin 2008, 47:127-131.
  • Freudenberg LS, Jentzen W, Müller SP, Bockisch A: Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to (124)I PET. Eur J Nucl Med Mol Imaging 2008, 35:502-508.
  • Freudenberg LS, Rosenbaum-Krumme SJ, Bockisch A, Eberhardt W, Frilling A: Cancer of unknown primary. Recent Results Cancer Res 2008, 170:193-202.
  • Heusner TA, Freudenberg LS, Kuehl H, Hauth EA, Veit-Haibach P, Forsting M, Bockisch A, Antoch G: Whole-body PET/CT-mammography for staging breast cancer: initial results. Br J Radiol 2008, 81:743-748.
  • Heusner TA, Kuehl H, Veit-Haibach P, Hahn S, Boy C, Forsting M, Bockisch A, Antoch G: Highly iodinated intravenous contrast material for PET/CT - a feasibility study. Rofo 2008, 180:740-745.
  • Heusner TA, Kuemmel S, Umutlu L, Koeninger A, Freudenberg LS, Hauth EA, Kimmig KR, Forsting M, Bockisch A, Antoch G: Breast cancer staging in a single session: whole-body PET/CT mammography. J Nucl Med 2008, 49:1215-1222.
  • Hilgard P, Antoch G, Ertle JM, ElFouly AH, Hamami M, Bockisch A, Gerken G: RADIOEMBOLIZATION WITH YTTRIUM-90 GLASS MICROSPHERES FOR ADVANCED HEPATOCELLULAR CARCINOMA: RESULTS FROM A EUROPEAN PILOT PHASE II STUDY. Hepatology 2008, 48:1444.
  • Israel I, Brandau W, Farmakis G, Samnick S: Improved synthesis of no-carrier-added p-[124I]iodo-L-phenylalanine and p-[131I]iodo-L-phenylalanine for nuclear medicine applications in malignant gliomas. Appl Radiat Isot 2008, 66:513-522.
  • Jentzen W, Freudenberg L, Eising EG, Sonnenschein W, Knust J, Bockisch A: Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med 2008, 49:1017-1023.
  • Jentzen W, Görges R, Freudenberg L, Eising EG, Müller SP, Bockisch A: Influence of various geometric factors on the iodine-131 uptake measurement for solitary thyroid nodules. Nucl Med Commun 2008, 29:398-404.
  • Jentzen W, Weise R, Kupferschläger J, Freudenberg L, Brandau W, Bares R, Burchert W, Bockisch A: Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems. Eur J Nucl Med Mol Imaging 2008, 35:611-623.
  • Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H, Klutmann S, Knapp WH, Zijlstra JM, Bockisch A, et al: Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008, 112:3989-3994.
  • Kuehl H, Antoch G, Bockisch A, Forsting M: Where there is no PET/CT. Eur J Radiol 2008, 67:372.
  • Kuehl H, Antoch G, Stergar H, Veit-Haibach P, Rosenbaum-Krumme S, Vogt F, Frilling A, Barkhausen J, Bockisch A: Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: initial results. Eur J Radiol 2008, 67:362-371.
  • Kuehl H, Eggebrecht H, Boes T, Antoch G, Rosenbaum S, Ladd S, Bockisch A, Barkhausen J, Erbel R: Detection of inflammation in patients with acute aortic syndrome: comparison of FDG-PET/CT imaging and serological markers of inflammation. Heart 2008, 94:1472-1477.
  • Kuehl H, Rosenbaum-Krumme S, Veit-Haibach P, Stergar H, Forsting M, Bockisch A, Antoch G: Impact of whole-body imaging on treatment decision to radio-frequency ablation in patients with malignant liver tumors: comparison of [18F]fluorodeoxyglucose-PET/computed tomography, PET and computed tomography. Nucl Med Commun 2008, 29:599-606.
  • Kuehl H, Stattaus J, Hertel S, Hunold P, Kaiser G, Bockisch A, Forsting M: Mid-term Outcome of Positron Emission Tomography/Computed Tomography-assisted Radiofrequency Ablation in Primary and Secondary Liver Tumours - A Single-centre Experience. Clin Oncol (R Coll Radiol) 2008, 20:234-240.
  • Li J, Kuehl H, Grabellus F, Müller SP, Radunz S, Antoch G, Nadalin S, Broelsch CE, Gerken G, Paul A, Kaiser GM: Preoperative assessment of hilar cholangiocarcinoma by dual-modality PET/CT. J Surg Oncol 2008, 98:438-443.
  • Loetscher T, Bockisch CJ, Brugger P: Looking for the answer: The mind's eye in number space. Neuroscience 2008, 151:725-729.
  • Matuszczyk A, Petersenn S, Bockisch A, Gorges R, Sheu SY, Veit P, Mann K: Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res 2008, 40:210-213.
  • Rosenbaum SJ, Stergar H, Antoch G, Veit P, Bockisch A, Kühl H: Gastrointestinal tumors and PET/CT. Abdom Imaging 2008. 29. Semmler-Behnke M, Kreyling WG, Lipka J, Fertsch S, Wenk A, Takenaka S, Schmid G, Brandau W: Biodistribution of 1.4- and 18-nm gold particles in rats. Small 2008, 4:2108-2111.
  • Heinzel A, Steinke R, Poeppel TD, Grosser O, Bogerts B, Otto H, Northoff G. S-ketamine and GABA-A-receptor interaction in humans: an exploratory study with I-123-iomazenil SPECT. Hum Psychopharmacol
  • Poeppel TD, Krause BJ Functional imaging of memory processes in humans: Positron emission tomography and functional magnetic resonance imaging Methods
  • Koppelstaetter F, Poeppel TD, Siedentopf CM, Ischebeck A, Verius M, Haala I, Mottaghy FM, Rhomberg P, Golaszewski S, Gotwald T, Lorenz IH, Kolbitsch C, Felber S, Krause BJ Does caffeine modulate verbal working memory processes? An fMRI study Neuroimage
  • Heinzel A, Hautzel H, Poeppel TD, Boers F, Beu M, Mueller HW.Neural correlates of subliminal and supraliminal letter processing--an event-related fMRI study. Conscious Cogn
  • Bockisch A, Grunwald F: EANM president elected. Nuklearmedizin 2007, 46:N7-N7.
  • Brandt AS, Soares SB, Fehr A, Kukuk S, Mathers MJ, Störkel S, Lerch H, Bockisch A, Haage P, Vollmann R, et al: [In Process Citation]. Urologe 2007, 46:1302-1304.
  • Eising EG, Jentzen W, Freudenberg L, Bockisch A: Value of low levels of anti-TPO antibodies in patients with suspicion of Hashimoto thyroiditis. Endocrinologist 2007, 17:83-84.
  • Eising EG, Jentzen W, Görges R, Freudenberg L, Bockisch A: Economic image compression of output documentation of the most frequent examinations in nuclear medicine. Acad Radiol 2007, 14:967-973.
  • Ertle J, Antoch G, Hamami M, Bockisch A, Gerken G, Hilgard P: Internal radiotherapy with (90)yttrium glass microspheres (therasphere) for locally advanced hepatocellular carcinoma: Prospective validation of safety and efficacy in a European pilot study. Hepatology 2007, 46 Suppl.:415A-415A.
  • Freudenberg L, Jentzen W, Gorges R, Petrich T, Bockisch A: Therapeutic impact of 1241 positron emission tomography dosimetry in advanced differentiated thyroid cancer. Horm Res 2007, 68 Suppl.:30-30.
  • Freudenberg LS, Frilling A, Kühl H, Müller SP, Jentzen W, Bockisch A, Antoch G: Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer. Eur Radiol 2007, 17:3139-3147.
  • Freudenberg LS, Jentzen W, Görges R, Petrich T, Marlowe RJ, Knust J, Bockisch A: 124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact. Nuklearmedizin 2007, 46:121-128.
  • Freudenberg LS, Jentzen W, Marlowe RJ, Koska WW, Luster M, Bockisch A: 124-iodine positron emission tomography/computed tomography dosimetry in pediatric patients with differentiated thyroid cancer. Exp Clin Endocrinol Diabetes 2007, 115:690-693.
  • Freudenberg LS, Rosenbaum SJ, Beyer T, Bockisch A, Antoch G: PET versus PET/CT dual-modality imaging in evaluation of lung cancer. Radiol Clin North Am 2007, 45:639-644, v.
  • Heusner TA, Fronz U, Jentzen W, Verhagen R, Forsting M, Bockisch A, Antoch G: [The Effect of Different Chemoembolization Materials on CT-Based Attenuation Correction in PET/CT.]. Rofo 2007, 179:1159-1165.
  • Jentzen W, Freudenberg L, Eising EG, Heinze M, Brandau W, Bockisch A: Segmentation of PET volumes by iterative image thresholding. J Nucl Med 2007, 48:108-114.
  • Kinner S, Antoch G, Bockisch A, Veit-Haibach P: Whole-body PET/CT-colonography: a possible new concept for colorectal cancer staging. Abdom Imaging 2007, 32:606-612.
  • Kobe C, Dietlein M, Franklin J, Pluetschow A, Eich HT, Fuchs M, Gossmann A, Pfistner B, Diehl V, Engert A, et al: FDG-PET for assessment of residual tissue after completion of chemotherapy in Hodgkin lymphoma - Report on the second interim analysis of the pet investigation in the trial HD15 of the GHSG. Haematologica Hematol J 2007, 92 Suppl.:31-32.
  • Krause BJ, Beyer T, Bockisch A, Delbeke D, Kotzerke J, Minkov V, Reiser M, Willich N: [FDG-PET/CT in oncology. German Guideline]. Nuklearmedizin 2007, 46:291-301.
  • Krohn T, Kaiser HJ, Gagel B, Boy C, Schaefer WM, Buell U, Zimny M: [3D volume and SUV analysis of oncological PET studies: a voxel-based image processing tool with NSCLC as example]. Nuklearmedizin 2007, 46:141-148.
  • Kuehl H, Veit P, Rosenbaum SJ, Bockisch A, Antoch G: Can PET/CT Replace Separate Diagnostic CT for Cancer Imaging? Optimizing CT Protocols for Imaging Cancers of the Chest and Abdomen. J Nucl Med 2007, 48 Suppl 1:45S-57S.
  • Leinung S, Wittekind C, Helmberger T, Wurl P, Bockisch A, Schoppmeyer K: Mesenchymal tumors of the gastrointestinal tract. Chir Gastroenterologie 2007, 23:166-171.
  • Matuszczyk A, Petersenn S, Lahner H, Haude M, Veit P, Becker JU, Kimmig R, Bockisch A, Mann K: [Leydig cell tumor as a cause of hirsutism in a postmenopausal woman.]. Med Klin (Munich) 2007, 102:259-262.
  • Meyer PT, Elmenhorst D, Boy C, Winz O, Matusch A, Zilles K, Bauer A: Effect of aging on cerebral A1 adenosine receptors: A [18F]CPFPX PET study in humans. Neurobiol Aging 2007, 28:1914-1924.
  • Nassenstein K, Veit-Haibach P, Stergar H, Gutzeit A, Freudenberg L, Kuehl H, Fischer M, Barkhausen J, Bockisch A, Antoch G: Cervical Lymph Node Metastases of Unknown Origin: Primary Tumor Detection with Whole-Body Positron Emission Tomography/Computed Tomography. Acta Radiol 2007:1-8.
  • Nassenstein K, Veit-Haibach P, Stergar H, Gutzeit A, Freudenberg L, Kuehl H, Fischer M, Barkhausen J, Bockisch A, Antoch G: Cervical lymph node metastases of unknown origin: Primary tumor detection with whole-body positron emission tomography/computed tomography. Acta Radiol 2007, 48:1101-1108.
  • Pan Y, Neuss S, Leifert A, Fischler M, Wen F, Simon U, Schmid G, Brandau W, Jahnen-Dechent W: Size-dependent cytotoxicity of gold nanoparticles. Small 2007, 3:1941-1949.
  • Poettgen C, Theegarten D, Eberhardt W, Levegruen S, Gauler T, Krbek T, Stamatis G, Teschler H, Kuehl H, Bockisch A, Stuschke M: Correlation of PET/CT findings and histopathology after neoadjuvant therapy in non-small cell lung cancer. Oncology 2007, 73:316-323.
  • Pottgen C, Berkovic K, Gauler T, Krbek T, Welter S, Gohlert A, Grehl S, Teschler H, Stamatis G, Bockisch A, et al: What value does the F-18-FDG-Signal have in functional imaging after definitive chemo-radiotherapy of locally advanced lung cancers? Strahlenther Onkol 2007, 183 Suppl.:41-42.
  • Pottgen C, Gauler T, Krbek T, Theegarten D, Muller S, Levegrun S, Teschler H, Stamatis G, Bockisch A, Eberhardt W, Stuschke M: Prognostic value of F-18-FDG-PET/CT progression examinations during neoadjuvant chemoradiotherapy in locally advanced NSCLC. Strahlenther Onkol 2007, 183 Suppl.:44-44.
  • Stergar H, Bockisch A, Eschmann SM, Krause BJ, Rödel R, Tiling R, Weckesser M: Influence of PET/CT-introduction on PET scanning frequency and indications. Results of a multicenter study. Nuklearmedizin 2007, 46:57-64.
  • Sterner T, Pink R, Freudenberg L, Jentzen T, Quitmann H, Bockisch A, Löer F: The role of [18F]fluoride positron emission tomography in the early detection of aseptic loosening of total knee arthroplasty. Int J Surg 2007, 5:99-104.
  • Tagay S, Senf W, Schöpper N, Mewes R, Bockisch A, Görges R: [Protective factors for anxiety and depression in thyroid cancer patients.]. Z Psychosom Med Psychother 2007, 53:62-74.
  • Tsakiris M, Hesse MD, Boy C, Haggard P, Fink GR: Neural signatures of body ownership: a sensory network for bodily self-consciousness. Cereb Cortex 2007, 17:2235-2244.
  • Veit-Haibach P, Antoch G, Beyer T, Stergar H, Schleucher R, Hauth EA, Bockisch A: FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy. Br J Radiol 2007, 80:508-515.
  • Veit-Haibach P, Luczak C, Wanke I, Fischer M, Egelhof T, Beyer T, Dahmen G, Bockisch A, Rosenbaum S, Antoch G: TNM staging with FDG-PET/CT in patients with primary head and neck cancer. Eur J Nucl Med Mol Imaging 2007, 34:1953-1962.
  • Vogt FM, Antoch G, Veit P, Freudenberg LS, Blechschmid N, Diersch O, Bockisch A, Barkhausen J, Kuehl H: Morphologic and functional changes in nontumorous liver tissue after radiofrequency ablation in an in vivo model: comparison of 18F-FDG PET/CT, MRI, ultrasound, and CT. J Nucl Med 2007, 48:1836-1844.
  • Berding G, Schneider U, Gielow P, Buchert R, Donnerstag F, Brandau W, Knapp WH, Emrich HM, Müller-Vahl K: Feasibility of central cannabinoid CB1 receptor imaging with [124I]AM281 PET demonstrated in a schizophrenic patient. Psychiatry Res 2006, 147:249-256.
  • Beyer T, Bockisch A, Kühl H, Martinez MJ: Whole-Body 18F-FDG PET/CT in the Presence of Truncation Artifacts. J Nucl Med 2006, 47:91-99.
  • Bockisch A, Freudenberg L, Rosenbaum S, Jentzen W: (124)I in PET imaging: impact on quantification, radiopharmaceutical development and distribution. Eur J Nucl Med Mol Imaging 2006, 33:1247-1248.
  • Freudenberg LS, Beyer T, Müller SP, Görges R, Hopfenbach A, Bockisch A: [Evil radioactivity. Subjective perception of radioactivity in patients with thyroid disease prior to treatment with radioiodine]. Nuklearmedizin 2006, 45:229-234.
  • Frilling A, Malago M, Weber F, Paul A, Nadalin S, Sotiropoulos GC, Cicinnati V, Beckebaum S, Bockisch A, Mueller-Brand J, et al: Liver transplantation for patients with metastatic endocrine tumors: single-center experience with 15 patients. Liver Transpl 2006, 12:1089-1096.
  • Frilling A, Weber F, Saner F, Bockisch A, Hofmann M, Mueller-Brand J, Broelsch CE: Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery 2006, 140:968-976; discussion 976.
  • Frings M, Awad N, Jentzen W, Dimitrova A, Kolb FP, Diener HC, Timmann D, Maschke M: Involvement of the human cerebellum in short-term and long-term habituation of the acoustic startle response: A serial PET study. Clin Neurophysiol 2006, 117:1290-1300
  • 8. Grunwald T, Bockisch B, Spillner E, Ring J, Bredehorst R, Ollert MW: Molecular cloning and expression in insect cells of honeybee venom allergen acid phosphatase (Api m 3). J Allergy Clin Immunol 2006, 117:848-854.
  • Jentzen W, Schneider E, Freudenberg L, Eising EG, Gorges R, Muller SP, Brandau W, Bockisch A: Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer. Nucl Med Commun 2006, 27:669-676.
  • Matuszczyk A, Petersenn S, Bockisch A, Shen S, Veit P, Mann K: Chemotherapy with doxorubin in progredient medullary, follicular and papillary thyroid gland cancer. Med Klin 2006, 101:A17-A17.
  • Pöttgen C, Levegrün S, Theegarten D, Marnitz S, Grehl S, Pink R, Eberhardt W, Stamatis G, Gauler T, Antoch G, et al: Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006, 12:97-106.
  • Rosenbaum SJ, Lind T, Antoch G, Bockisch A: False-positive FDG PET uptake--the role of PET/CT. Eur Radiol 2006, 16:1054-1065.
  • Rosenbaum SJ, Stergar H, Antoch G, Veit P, Bockisch A, Kühl H: Staging and follow-up of gastrointestinal tumors with PET/CT. Abdom Imaging 2006, 31:25-35.
  • Tagay S, Herpertz S, Langkafel M, Erim Y, Bockisch A, Senf W, Görges R: Health-related Quality of Life, depression and anxiety in thyroid cancer patients. Qual Life Res 2006, 15:695-703.
  • Veit P, Antoch G, Stergar H, Bockisch A, Forsting M, Kuehl H: Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results. Eur Radiol 2006, 16:80-87.
  • Veit P, Kuehle C, Beyer T, Kuehl H, Bockisch A, Antoch G: Accuracy of combined PET/CT in image-guided interventions of liver lesions: an ex-vivo study. World J Gastroenterol 2006, 12:2388-2393.
  • Veit P, Kühle C, Beyer T, Kuehl H, Herborn CU, Börsch G, Stergar H, Barkhausen J, Bockisch A, Antoch G: Whole body positron emission tomography/computed tomography (PET/CT) tumour staging with integrated PET/CT colonography: technical feasibility and first experiences in patients with colorectal cancer. Gut 2006, 55:68-73.
  • Veit P, Ruehm S, Kuehl H, Stergar H, Mueller S, Bockisch A, Antoch G: Lymph node staging with dual-modality PET/CT: enhancing the diagnostic accuracy in oncology. Eur J Radiol 2006, 58:383-389.
  • Veit-Haibach P, Kuehle CA, Beyer T, Stergar H, Kuehl H, Schmidt J, Börsch G, Dahmen G, Barkhausen J, Bockisch A, Antoch G: Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography. JAMA 2006, 296:2590-2600.
  • Wittig A, Sauerwein W, Kaiser G, Grabellus F, Muller SP, Kuehl H, Antoch G, Muller AB, Broesch CE, Stuschke M, et al: Effects of an intraoperative radiation therapy (IORT) of the liver hilus after arrangement of a hepaticojejunostomy: Examinations by means of PET/CT in the pig. Strahlenther Onkol 2006, 182 Suppl.:89-89.
  • Abu Jawad J, Pottgen C, Horst E, Schenck M, Bockisch A, Stuschke M: FDG-PET/CT in seminoma: Up-staging before adjuvant radiotherapy. Strahlenther Onkol 2005, 181 Suppl.:79-79.
  • Antoch G, Vogt FM, Veit P, Freudenberg LS, Blechschmid N, Dirsch O, Bockisch A, Forsting M, Debatin JF, Kuehl H: Assessment of liver tissue after radiofrequency ablation: findings with different imaging procedures. J Nucl Med 2005, 46:520-525.
  • Beyer T, Antoch G, Bockisch A, Stattaus J: Optimized intravenous contrast administration for diagnostic whole-body 18F-FDG PET/CT. J Nucl Med 2005, 46:429-435.
  • Beyer T, Bockisch A, Schober O: 1 + 1 = 3. Nuklearmedizin 2005, 44 Suppl 1:S1.
  • Beyer T, Rosenbaum S, Veit P, Stattaus J, Müller SP, Difilippo FP, Schöder H, Mawlawi O, Roberts F, Bockisch A, Kühl H: Respiration artifacts in whole-body (18)F-FDG PET/CT studies with combined PET/CT tomographs employing spiral CT technology with 1 to 16 detector rows. Eur J Nucl Med Mol Imaging 2005, 32:1429-1439.
  • Beyer T, Tellmann L, Nickel I, Pietrzyk U: On the use of positioning aids to reduce misregistration in the head and neck in whole-body PET/CT studies. J Nucl Med 2005, 46:596-602.
  • Bockisch A, Rosenbaum S: [Has the development of PET come to an end with PET/CT?]. Rofo 2005, 177:14-16.
  • Eising EG, Jentzen W: The (usually) comfortable life with the fiction of chance. Dtsch Med Wochenschr 2005, 130:270-270.
  • Freudenberg LS, Fischer M, Antoch G, Jentzen W, Gutzeit A, Rosenbaum SJ, Bockisch A, Egelhof T: Dual modality of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography in patients with cervical carcinoma of unknown primary. Med Princ Pract 2005, 14:155-160.
  • Freudenberg LS, Sheu S, Görges R, Mann K, Bokler S, Frilling A, Schmid KW, Bockisch A, Otterbach F: Prognostic value of c-erbB-2 expression in papillary thyroid carcinoma. Nuklearmedizin 2005, 44:179-182, 184.
  • Frings M, Antoch G, Knorn P, Freudenberg L, Bier U, Timmann D, Maschke M: Strategies in detection of the primary tumour in anti-Yo associated paraneoplastic cerebellar degeneration. J Neurol 2005, 252:197-201.
  • Görges R, Maniecki M, Jentzen W, Sheu SN, Mann K, Bockisch A, Janssen OE: Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur J Endocrinol 2005, 153:49-55.
  • Gutzeit A, Antoch G, Kühl H, Egelhof T, Fischer M, Hauth E, Goehde S, Bockisch A, Debatin J, Freudenberg L: Unknown primary tumors: detection with dual-modality PET/CT--initial experience. Radiology 2005, 234:227-234.
  • Hauth EA, Antoch G, Stattaus J, Kuehl H, Veit P, Bockisch A, Kimmig R, Forsting M: Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer. Eur J Radiol 2005, 56:263-268.
  • Kröger K, Antoch G, Goyen M, Freudenberg LS, Veit P, Janicke I, Bockisch A, Forsting M: Positron emission tomography/computed tomography improves diagnostics of inflammatory arteritis. Heart Vessels 2005, 20:179-183.
  • Kuehle CA, Veit P, Antoch G, Grabellus F, Robert P, Beyer T, Herborn CU: Contrast-enhanced dark lumen PET/CT and MR colonography in a rodent polyp model: initial results with histopathologic correlation. AJR Am J Roentgenol 2005, 185:1045-1047.
  • Muller SP, Abbey CK, Rybicki FJ, Moore SC, Kijewski MF: Measures of performance in nonlinear estimation tasks: Prediction of estimation performance at low signal-to-noise ratio. Phys Med Biol 2005, 50:3697-3715.
  • Pottgen C, Levegrun S, Grehl S, Marnitz S, Gauler T, Muller S, Pink R, Kuhl H, Beyer T, Bockisch A, et al: Preoperative re-staging by means of PET/CT after neoadjuvant chemoradiation therapy in local advanced NSCLC: are serial examinations necessary? Strahlenther Onkol 2005, 181 Suppl.:31-31.
  • Stattaus J, Bockisch A, Forsting M, Müller SP: [Value of imaging for lymph node metastases from renal cell, bladder, prostate, penile, and testicular cancers]. Urologe A 2005, 44:614-624.
  • Stuschke M, Poettgen C, Gauler T, Korfee S, Bildat S, Goehlert A, Stamatis G, Krbek T, Teschler H, Bockisch A, Eberhardt W: PET/CT for patients (pts) selection within a multimodality treatment protocol (CTx + CTx/RTx +/- S) in Pts with locally advanced (LAD) non-small cell lung cancer (NSCLC)(inoperable stage IIIA/selected IIIB). Int J Radiat Oncol Biol Phys 2005, 63:S410-411.
  • Tagay S, Herpertz S, Langkafel M, Erim Y, Freudenberg L, Schöpper N, Bockisch A, Senf W, Görges R: Health-related quality of life, anxiety and depression in thyroid cancer patients under short-term hypothyroidism and TSH-suppressive levothyroxine treatment. Eur J Endocrinol 2005, 153:755-763.
  • Antoch G, Freudenberg LS, Beyer T, Bockisch A, Debatin JF: To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med 2004, 45 Suppl 1:56S-65S.
  • Antoch G, Fronz U, Veit P, Freudenberg LS, Jentzen W, Brandau W, Bockisch A, Verhagen R: Effect of chemoembolizing agents on the CT-based PET attenuation correction in dual-modality PET/CT. Eur J Nucl Med Mol Imaging 2004, 31 Suppl.:S331-S331.
  • Antoch G, Kaiser GM, Mueller AB, Metz KA, Zhang H, Kuehl H, Westermann S, Broelsch CE, Mueller SP, Bockisch A, Debatin JF: Intraoperative radiation therapy in liver tissue in a pig model: monitoring with dual-modality PET/CT. Radiology 2004, 230:753-760.
  • Antoch G, Kanja J, Bauer S, Kuehl H, Renzing-Koehler K, Schuette J, Bockisch A, Debatin JF, Freudenberg LS: Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004, 45:357-365.
  • Antoch G, Kuehl H, Kanja J, Lauenstein TC, Schneemann H, Hauth E, Jentzen W, Beyer T, Goehde SC, Debatin JF: Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation. Radiology 2004, 230:879-885.
  • Antoch G, Saoudi N, Freudenberg LS, Kuehl H, Mueller SP, Beyer T, Bockisch A, Debatin JF: Accuracy of whole-body FDG-PET/CT for tumor staging in oncology. Eur J Nucl Med Mol Imaging 2004, 31 Suppl.:S285-S285.
  • Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller SP, Beyer T, Bockisch A, Debatin JF, Freudenberg LS: Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 2004, 22:4357-4368.
  • Antoch G, Veit P, Vogt FM, Freudenberg LS, Dirsch O, Bockisch A, Debatin JF, Kuehl H: Appearance of rim-like hyperperfusion and tissue regeneration following hepatic radiofrequency ablation: Findings with different imaging procedures. Eur J Nucl Med Mol Imaging 2004, 31 Suppl.:S294-S294.
  • Antoch G, Vogt FM, Bockisch A, Ruehm SG: [Whole-body tumor staging: MRI or FDG-PET/CT?]. Radiologe 2004, 44:882-888.
  • Beyer T, Antoch G, Fehlings T, Rosenbaum S, Freudenberg LS, Stattaus J: Optimized IV contrast administration protocols for diagnostic FDG-PET/CT imaging. Eur J Nucl Med Mol Imaging 2004, 31 Suppl.:S286-S286.
  • Beyer T, Antoch G, Müller S, Egelhof T, Freudenberg LS, Debatin J, Bockisch A: Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med 2004, 45 Suppl 1:25S-35S.
  • Beyer T, Muller SP, Terschuren B, Stergar H, Kuehl H, Bockisch A: Effect of dental implants on tracer distribution in FDG-PET and FDG-PET/CT. Eur J Nucl Med Mol Imaging 2004, 31 Suppl.:S409-S409.
  • Bockisch A, Beyer T, Antoch G, Freudenberg LS, Kühl H, Debatin JF, Müller SP: Positron emission tomography/computed tomography--imaging protocols, artifacts, and pitfalls. Mol Imaging Biol 2004, 6:188-199.
  • Bockisch A, Beyer T, Antoch G, Veit P, Müller S, Pink R, Rosenbaum S, Kühl H: [Principles of PET/CT and clinical application.]. Radiologe 2004, 44:1045-1054.
  • Freudenberg LS, Antoch G, Jentzen W, Pink R, Knust J, Görges R, Müller SP, Bockisch A, Debatin JF, Brandau W: Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol 2004, 14:2092-2098.
  • Freudenberg LS, Antoch G, Schütt P, Beyer T, Jentzen W, Müller SP, Görges R, Nowrousian MR, Bockisch A, Debatin JF: FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 2004, 31:325-329.
  • Freudenberg LS, Schueler AO, Beyer T, Antoch G, Kühl H, Bornfeld N, Bockisch A, Egelhof T: Whole-body fluorine-18 fluordeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in staging of advanced uveal melanoma. Surv Ophthalmol 2004, 49:537-540.
  • Frilling A, Tecklenborg K, Weber F, Kühl H, Müller S, Stamatis G, Broelsch C: Importance of adrenal incidentaloma in patients with a history of malignancy. Surgery 2004, 136:1289-1296.
  • Herrmann BL, Baumann H, Janssen OE, Görges R, Schmid KW, Mann K: Impact of disease activity on thyroid diseases in patients with acromegaly: basal evaluation and follow-up. Exp Clin Endocrinol Diabetes 2004, 112:225-230.
  • Hofmann M, Beyer T, Boerner AR, Mueller JA, Frilling A, Maecke H, Muller S, Clauss R, Bockisch A, Knapp WH: Improved imaging of SMS PET (GA-68-DOTATOC) by PET/CT in carcinoids. Eur J Nucl Med Mol Imaging 2004, 31 Suppl.:S339-S339.
  • Veit P, Antoch G, Freudenberg L, Bockisch A, Forsting M, Kuehl H: Efficacy of dual modality PET/CT in post interventional surveillance of radiofrequency-ablation in liver metastasis of colorectal cancer: Preliminary results. Eur J Nucl Med Mol Imaging 2004, 31:S331-S331.
  • Veit P, Gutzeit A, Hauth E, Freudenberg L, Bockisch A, Debatin J, Antoch G: Dual-modality PET/CT for detection of unknown primary tumors. Eur J Nucl Med Mol Imaging 2004, 31 Suppl.:S339-S339.
  • Antoch G, Freudenberg LS, Debatin JF, Kröger K: Images in vascular medicine. Diagnosis of giant cell arteritis with PET/CT. Vasc Med 2003, 8:281-282.
  • Antoch G, Freudenberg LS, Nemat AT, Beyer T, Bockisch A, Debatin JF: Preoperative staging of non-small cell lung cancer with dual-modality PET/CT imaging: A comparison with PET and CT. J Nucl Med 2003, 44 Suppl.:172P-172P.
  • Antoch G, Jentzen W, Freudenberg LS, Stattaus J, Mueller SP, Debatin JF, Bockisch A: Effect of oral contrast agents on computed tomography-based positron emission tomography attenuation correction in dual-modality positron emission tomography/computed tomography imaging. Invest Radiol 2003, 38:784-789.
  • Antoch G, Kanja J, Freudenberg LS, Bauer S, Schuette J, Bockisch A, Debatin JF: Comparison of PET, CT, and dual-modality PET/CT for monitoring of Imatinib (ST1571) therapy in patients with gastrointestinal stromal tumors (GIST). J Nucl Med 2003, 44 Suppl.:24P-24P.
  • Antoch G, Kuehl H, Kanja J, Beyer T, Bockisch A, Debatin JF: Contrast-induced artefacts in dual-modality PET/CT: Can a negative oral contrast agent solve the problem? J Nucl Med 2003, 44 Suppl.:377P-377P.
  • Antoch G, Stattaus J, Nemat AT, Marnitz S, Beyer T, Kuehl H, Bockisch A, Debatin JF, Freudenberg LS: Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 2003, 229:526-533.
  • Antoch G, Vogt FM, Freudenberg LS, Nazaradeh F, Goehde SC, Barkhausen J, Dahmen G, Bockisch A, Debatin JF, Ruehm SG: WHOLE-BODY DUAL-MODALITY PET/CT AND WHOLE-BODY MRI FOR TUMOR STAGING IN ONCOLOGY. JAMA 2003, 290:3199-3206.
  • Antoch G, Vogt FM, Freudenberg LS, Ruehm SG, Bockisch A, Debatin JF: Whole-body tumor staging: Comparison of MRI and dual-modality PET/CT. J Nucl Med 2003, 44 Suppl.:380P-380P.
  • Bauer S, Corless CL, Heinrich MC, Dirsch O, Antoch G, Kanja J, Seeber S, Schütte J: Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. Cancer Chemother Pharmacol 2003, 51:261-265.
  • Bengel FM, Anton M, Richter T, Simoes MV, Haubner R, Henke J, Erhardt W, Reder S, Lehner T, Brandau W, et al: Noninvasive imaging of transgene expression by use of positron emission tomography in a pig model of myocardial gene transfer. Circulation 2003, 108:2127-2133.
  • Beyer T, Antoch G, Blodgett T, Freudenberg LF, Akhurst T, Mueller S: Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging 2003, 30:588-596.
  • Beyer T, Orth U, Freudenberg L, Antoch G, Mueller S, Bockisch A: Standardized uptake values in whole-body FDG-PET/CT after CT-based attenuation correction. J Nucl Med 2003, 44 Suppl.:259P-259P.
  • Bockisch A: Greetings: 41st Annual DGN Meeting. Nuklearmedizin 2003, 42:54-54.
  • Bockisch A, Brandt-Mainz K, Görges R, Müller S, Stattaus J, Antoch G: Diagnosis in medullary thyroid cancer with [18F]FDG-PET and improvement using a combined PET/CT scanner. Acta Med Austriaca 2003, 30:22-25.
  • Freudenberg LS, Antoch G, Beyer T, Görges R, Debatin JF, Bockisch A: Diagnosis of labia metastasis by F-18 FDG PET and CT fusion imaging in sarcoma follow-up. Clin Nucl Med 2003, 28:636-637.
  • Freudenberg LS, Antoch G, Görges R, Knust J, Pink R, Jentzen W, Debatin JF, Brandau W, Bockisch A, Stattaus J: Combined PET/CT with iodine-124 in diagnosis of spread metastatic thyroid carcinoma: a case report. Eur Radiol 2003, 13 Suppl 4:L19-23.
  • Freudenberg LS, Antoch G, Mueller SP, Goerges R, Bockisch A: Whole body FDG-PET/CT in restaging of lymphoma. J Nucl Med 2003, 44 Suppl.:83P-84P.
  • Freudenberg LS, Beyer T, Bockisch A: Improving perceptions of the quality of service in nuclear medicine. Eur J Nucl Med Mol Imaging 2003, 30:472.
  • Görges R, Brandt-Mainz K, Freudenberg L, Frilling A, Grimm W, Bockisch A: [Kontinuierliche Sensitivitätssteigerung in der Schilddrüsenkarzinom-Nachsorge im Verlauf dreier Thyreoglobulin-IMA-Generationen]. Nuklearmedizin 2003, 42:157-166.
  • Görges R, Eising EG, Fotescu D, Renzing-Köhler K, Frilling A, Schmid KW, Bockisch A, Dirsch O: Diagnostic value of high-resolution B-mode and power-mode sonography in the follow-up of thyroid cancer. Eur J Ultrasound 2003, 16:191-206.
  • Gorges R, Freudenberg L, Brandt-Mainz K, Frilling A, Bockisch A: Clinical evaluation of a new, highly sensitive thyroglobulin assay. J Nucl Med 2003, 44 Suppl.:326P-326P.
  • Görges R, Liedke MO, Worm K, Frilling A, Bockisch A, Schmid KW: [Rapid diagnosis of recurrence of a tall cell variant of papillary thyroid cancer by endogenous TSH stimulation]. Nuklearmedizin 2003, 42:N15-18.
  • Hengge UR, Stocks K, Faulkner S, Wiehler H, Lorenz C, Jentzen W, Hengge D, Ringham G: Oxymetholone for the treatment of HIV-wasting: a double-blind, randomized, placebo-controlled phase III trial in eugonadal men and women. HIV Clin Trials 2003, 4:150-163.
  • Hengge UR, Stocks K, Wiehler H, Faulkner S, Esser S, Lorenz C, Jentzen W, Hengge D, Goos M, Dudley RE, Ringham G: Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting. AIDS 2003, 17:699-710.
  • Herrmann BL, Brandt-Mainz K, Saller B, Bruch C, Wieneke H, Kügler C, Ferdin S, Hahn S, Erbel R, Bockisch A, Mann K: Myocardial perfusion abnormalities in patients with active acromegaly. Horm Metab Res 2003, 35:183-188.
  • Kinahan PE, Hasegawa BH, Beyer T: X-ray-based attenuation correction for positron emission tomography/computed tomography scanners. Semin Nucl Med 2003, 33:166-179.
  • Maschke M, Erichsen M, Drepper J, Jentzen W, Müller SP, Kolb FP, Diener HC, Timmann D: Cerebellar representation of the eyeblink response as revealed by PET. Neuroreport 2003, 14:1371-1374. 28. Schmid KW, Sheu SY, Görges R, Ensinger C, Tötsch M: [Thyroid tumors]. Pathologe 2003, 24:357-372. 29. Sheu SY, Görges R, Schmid KW: [Hyperplasia of the thyroid gland]. Pathologe 2003, 24:348-356. 30. Townsend DW, Beyer T, Blodgett TM: PET/CT scanners: a hardware approach to image fusion. Semin Nucl Med 2003, 33:193-204.
  • Antoch G, Egelhof T, Korfee S, Frings M, Forsting M, Bockisch A: Recurrent schwannoma: diagnosis with PET/CT. Neurology 2002, 59:1240.
  • Antoch G, Freudenberg LS, Egelhof T, Stattaus J, Bockisch A, Debatin JF: Effect of contrast agent bolus passage on dual-modality PET/CT imaging. Radiology 2002, 225 Suppl.:383-383.
  • Antoch G, Freudenberg LS, Egelhof T, Stattaus J, Jentzen W, Debatin JF, Bockisch A: Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. J Nucl Med 2002, 43:1339-1342.
  • Antoch G, Freudenberg LS, Stattaus J, Bockisch A, Debatin JF: Optimized CT-imaging with oral and intravenous contrast material in whole-body PET/CT. Radiology 2002, 225 Suppl.:636-636.
  • Antoch G, Freudenberg LS, Stattaus J, Jentzen W, Mueller SP, Debatin JF, Bockisch A: Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materials. AJR Am J Roentgenol 2002, 179:1555-1560.
  • Antoch G, Jentzen W, Stattaus J, Mueller SP, Bockisch A, Debatin JF: Effect of oral contrast agents on CT-based PET attenuation correction in dual-modality PET/CT tomography. Radiology 2002, 225 Suppl.:423-424.
  • Brandau W, Knust EJ, Dutschka K, Freudenberg L, Jentzen W, Bockisch A: Production of high activity, small volume I-124 solutions for PET/CT imaging. J Nucl Med 2002, 43 Suppl.:45P-45P.
  • Bruch C, Dagres N, Wieneke H, Herborn C, Brandt-Mainz K, Erbel R: [Sinus node dysfunction with intermittent sinus arrest and AV-nodal escape rhythm as initial manifestation of pheochromocytoma]. Z Kardiol 2002, 91:81-87.
  • Eising EG, Görges R, Freudenberg L, Kanja J, Bockisch A: Influence of therapy with iodine-131 on thyroid tissue pattern in colour and power Doppler sonography. Clin Radiol 2002, 57:646-651.
  • Eising EG, Jentzen W, Freudenberg L, Gorges R, Brandt-Mainz K, Bockisch A: NEW TENDENCIES IN RADIOLOGY - BRAVE NEW WORLD? Clin Exp Allergy 2002, 32:378-381.
  • Freudenberg L, Rosenbaum S: [Diagnosis of pulmonary artery embolism.. Part 1]. Dtsch Med Wochenschr 2002, 127:524.
  • Freudenberg LS, Antoch G, Gorges R, Knust EJ, Beyer T, Brandau W, Bockisch A, Debatin JF: I-124-PET/CT IN METASTATIC FOLLICULAR THYROID CARCINOMA. Eur J Nucl Med Mol Imaging 2002, 29:1106.
  • Freudenberg LS, Mueller S, Antoch G, Beyer T, Knust J, Goerges R, Jentzen WJ, Brandau W, Debatin J, Bockisch A: Value of I-124 PET/CT in staging of patients with differentiated thyroid cancer. J Nucl Med 2002, 43 Suppl.:280P-281P.
  • Frings M, Maschke M, Erichsen M, Jentzen W, Müller SP, Kolb FP, Diener HC, Timmann D: Involvement of the human cerebellum in fear-conditioned potentiation of the acoustic startle response: a PET study. Neuroreport 2002, 13:1275-1278.
  • Görges R, Antoch G, Brandau W, Freudenberg LS, Knust J, Dutschka K, Müller SP, Jentzen W, Bockisch A, Stattaus J: [Combination PET/CT with 124I positron rays in metastatic follicular thyroid carcinoma]. Nuklearmedizin 2002, 41:N68-71.
  • Görges R, Saller B, Eising EG, Quadbeck B, Mann K, Bockisch A: Surveillance of TSH-suppressive levothyroxine treatment in thyroid cancer patients: TRH testing versus basal TSH determination by a third generation assay. Exp Clin Endocrinol Diabetes 2002, 110:355-360.
  • Herrmann BL, Saller B, Janssen OE, Gocke P, Bockisch A, Sperling H, Mann K, Broecker M: Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene. J Clin Endocrinol Metab 2002, 87:5476-5484.
  • Hunold P, Brandt-Mainz K, Freudenberg L, Vogt FM, Neumann T, Knipp S, Barkhausen J: [Evaluation of myocardial viability with contrast-enhanced magnetic resonance imaging--comparison of the late enhancement technique with positronemission tomography]. Rofo 2002, 174:867-873.
  • Kiefl C, Sreerama N, Haddad R, Sun L, Jentzen W, Lu Y, Qiu Y, Shelnutt JA, Woody RW: Heme distortions in sperm-whale carbonmonoxy myoglobin: correlations between rotational strengths and heme distortions in MD-generated structures. J Am Chem Soc 2002, 124:3385-3394.
  • Lauenstein TC, Freudenberg LS, Goehde SC, Ruehm SG, Goyen M, Bosk S, Debatin JF, Barkhausen J: Whole-body MRI using a rolling table platform for the detection of bone metastases. Eur Radiol 2002, 12:2091-2099.
  • Maschke M, Erichsen M, Drepper J, Jentzen W, Müller SP, Kolb FP, Diener HC, Timmann D: Limb flexion reflex-related areas in human cerebellum. Neuroreport 2002, 13:2325-2330.
  • Müller BW, Jüptner M, Jentzen W, Müller SP: Cortical activation to auditory mismatch elicited by frequency deviant and complex novel sounds: a PET study. Neuroimage 2002, 17:231-239.
  • Nelles G, Jentzen W, Kleine K, Bockisch A, Diener HC: Neural substrates of good vs. bad recovery after hemiplegic stroke: A serial PET study. Stroke 2002, 33:416-416.
  • Saller B, Moeller L, Görges R, Janssen OE, Mann K: Role of conventional ultrasound and color Doppler sonography in the diagnosis of medullary thyroid carcinoma. Exp Clin Endocrinol Diabetes 2002, 110:403-407.

25. Simon D, Körber C, Krausch M, Segering J, Groth P, Görges R, Grünwald F, Müller-Gärtner HW, Schmutzler C, Köhrle J, et al: Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging 2002, 29:775-782.

26. Strumberg D, Brügge S, Korn MW, Koeppen S, Ranft J, Scheiber G, Reiners C, Möckel C, Seeber S, Scheulen ME: Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 2002, 13:229-236.

  • Brandt-Mainz K, von Mallek D, Pöttgen C, Eising EG, Bockisch A, Stuschke M, Sack H: Parametric oesophageal multiple swallow scintigraphy for validation of dysphageal symptoms during external beam irradiation of mediastinal tumours. Eur J Nucl Med 2001, 28:313-319.
  • Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, Lange H, Bredow J, Körber C, Grünwald F: Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 2001, 28:1671-1676.
  • Dittmann-Balçar A, Jüptner M, Jentzen W, Schall U: Dorsolateral prefrontal cortex activation during automatic auditory duration-mismatch processing in humans: a positron emission tomography study. Neurosci Lett 2001, 308:119-122.
  • Eising EG, Müller TH, Freudenberg L, Müller SP, Dutschka K, Sonnenschein W, Przuntek H, Bockisch A: SPECT imaging with [123I]-beta-CIT in Parkinsonism: comparison of SPECT images obtained by a single-headed and a three-headed gamma camera. Nucl Med Commun 2001, 22:145-150.
  • Frilling A, Tecklenborg K, Görges R, Weber F, Clausen M, Broelsch EC: Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg 2001, 234:804-811.
  • Görges R, Kahaly G, Müller-Brand J, Mäcke H, Roser HW, Bockisch A: Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. Thyroid 2001, 11:647-659.
  • Grötz KA, Wüstenberg P, Kohnen R, Al-Nawas B, Henneicke-von Zepelin HH, Bockisch A, Kutzner J, Naser-Hijazi B, Belz GG, Wagner W: Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutine in patients with head and neck cancer--a prospective,randomized, placebo-controlled, double-blind study. Br J Oral Maxillofac Surg 2001, 39:34-39.
  • Jacobs A, Bräunlich I, Graf R, Lercher M, Sakaki T, Voges J, Hesselmann V, Brandau W, Wienhard K, Heiss WD: Quantitative kinetics of [124I]FIAU in cat and man. J Nucl Med 2001, 42:467-475.
  • Kijewski MF, Moore SC, Jadvar H, Zimmerman RE, Muller SP: EFFECTS OF SPECT COLLIMATION AND SYSTEM GEOMETRY ON CLASSIFICATION TASKS RELATED TO PARKINSON'S DISEASE. IEEE Trans Nucl Sci 2001, 48:734-738.
  • Kopf D, Schmitz H, Beyer J, Frank M, Bockisch A, Lehnert H: A double-blind trial of perindopril and nitrendipine in incipient diabetic nephropathy. Diabetes Nutr Metab 2001, 14:245-252.
  • Leonhardt G, Bingel U, Spiekermann G, Kurthen M, Müller S, Hufnagel A: Cortical activation in patients with functional hemispherectomy. J Neurol 2001, 248:881-888.
  • Moore SC, Kijewski MF, Müller SP, Rybicki F, Zimmerman RE: Evaluation of scatter compensation methods by their effects on parameter estimation from SPECT projections. Med Phys 2001, 28:278-287.
  • Nelles G, Jentzen W, Jueptner M, Müller S, Diener HC: Arm training induced brain plasticity in stroke studied with serial positron emission tomography. Neuroimage 2001, 13:1146-1154.
  • Peters S, Eising EG, Przuntek H, Müller T: Vascular Parkinsonism: a case report and review of the literature. J Clin Neurosci 2001, 8:268-271.
  • Spitz J, Freudenberg LS: THE IMPACT OF NUCLEAR MEDICINE PROCEDURES ON THE DIAGNOSIS AND FOLLOW-UP OF AMYLOIDOSIS. Amyloid 2001, 8:170-174.
  • Brandt-Mainz K, Müller SP, Görges R, Saller B, Bockisch A: The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med 2000, 27:490-496.
  • Brandt-Mainz K, Müller SP, Reiners C, Bockisch A: [Relationship between thyroglobulin and reliability of thallium 201 scintigraphy in differentiated thyroid cancer]. Nuklearmedizin 2000, 39:20-25.
  • Engelbach M, Görges R, Forst T, Pfützner A, Dawood R, Heerdt S, Kunt T, Bockisch A, Beyer J: Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements. J Clin Endocrinol Metab 2000, 85:1890-1894.
  • Frilling A, Görges R, Clauer U, Tecklenborg K, Broelsch CE: [Minimally invasive parathyroidectomy with local anesthesia in conjunction with ultrasonography, sestamibi scintigraphy and intraoperative parathyroid hormone measurement]. Chirurg 2000, 71:1474-1479.
  • Frilling A, Görges R, Tecklenborg K, Gassmann P, Bockhorn M, Clausen M, Broelsch CE: Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma. Surgery 2000, 128:1067-1074.
  • Hengstler JG, Bockisch A, Fuchs J, Grimm W, Görges R, Oesch-Bartlomowicz B, Zapf AO, Lade K, Tanner B, Teichmann E, et al: Induction of DNA single-strand breaks by 131I and 99mTc in human mononuclear blood cells in vitro and extrapolation to the in vivo situation. Radiat Res 2000, 153:512-520.
  • Leonhardt G, Spiekermann G, Müller S, Zentner J, Hufnagel A: Cortical reorganization following multiple subpial transection in human brain - a study with positron emission tomography. Neurosci Lett 2000, 292:63-65.
  • Luster M, Reinhardt W, Korber C, Lassmann M, Haenscheid H, Michalowski U, Rendl J, Eising E, Mann K, Reiners C: The use of recombinant human TSH in a patient with metastatic follicular carcinoma and insufficient endogenous TSH production. J Endocrinol Invest 2000, 23:473-475.
  • Maschke M, Kolb FP, Drepper J, Peper M, Lachauer S, Müller SP, Diener HC, Timmann D: A possible role of the human cerebellum in conditioning of the jaw-opening reflex. Neurosci Lett 2000, 285:213-217.
  • Moore SC, Muller SP, Kijewski MF: ENERGY-BASED COMPENSATION FOR NONUNIFORM ATTENUATION IN GA-67SPECT IMAGING. IEEE Trans Nucl Sci 2000, 47:1149-1154.
  • Schleimer K, Lange R, Rauen U, Nowak B, Brandt-Mainz K, De Groot H, Erhard J: Auxiliary rat liver transplantation with portal vein arterialization in acute hepatic failure. Transplantation 2000, 70:73-78.
  • Walz MK, Metz KA, Görges R, Saller B, Mitchell A, Goering K, Peitgen K: [Endoscopic excision of extra-adrenal pheochromocytomas (paragangliomas)]. Chirurg 2000, 71:1504-1508.

Gemeinsam stark

Forschen und Heilen im Netzwerk des Universitätsklinikum Essen.

mehr